Results 61 to 70 of about 839,337 (241)

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

New England Journal of Medicine, 2020
Immunogenicity and Moderna’s SARS-CoV-2 Vaccine Thirty-four adults received two 100-μg injections of Moderna’s mRNA SARS-CoV-2 vaccine, and serum anti–spike protein and neutralizing antibody titers...
A. Widge, N. Rouphael, L. Jackson, E. Anderson, P. Roberts, M. Makhene, J. Chappell, M. Denison, Laura J. Stevens, A. Pruijssers, A. McDermott, B. Flach, Bob C. Lin, N. Doria-Rose, S. O'Dell, S. Schmidt, K. Neuzil, H. Bennett, B. Leav, M. Makowski, J. Albert, Kaitlyn A. Cross, V. Edara, K. Floyd, M. Suthar, Wendy L. Buchanan, C. Luke, J. Ledgerwood, J. Mascola, B. Graham, J. Beigel   +30 more
semanticscholar   +1 more source

Cellular and humoral response after MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients

American Journal of Transplantation, 2021
According to preliminary data, seroconversion after mRNA SARS‐CoV‐2 vaccination might be unsatisfactory in Kidney Transplant Recipients (KTRs). However, it is unknown if seronegative patients develop at least a cellular response that could offer a ...
D. Cucchiari, Natalia Egri, M. Bodro, S. Herrera, J. Del Risco-Zevallos, J. Casals-Urquiza, F. Cofan, A. Moreno, J. Rovira, E. Bañon-maneus, M. Ramirez-Bajo, P. Ventura-Aguiar, Anna Pérez-Olmos, Marta Garcia‐Pascual, M. Pascal, A. Vilella, A. Trilla, J. Ríos, E. Palou, M. Juan, Beatriu Bayés, F. Diekmann   +21 more
semanticscholar   +1 more source

Impact of Holding Immunosuppressive Therapy in Patients with Inflammatory Bowel Disease Around mRNA COVID-19 Vaccine Administration on Humoral Immune Response and Development of COVID-19 Infection [PDF]

, 2023
BACKGROUND AND AIMS: The BNT162b2 and mRNA-1273 COVID-19 vaccines are efficacious in patients with inflammatory bowel disease; but there is a lack of data examining if holding immunosuppressive therapy around vaccination improves immune response.
Cross, Raymond K, Farraye, Francis A, Hashash, Jana G, Kappelman, Michael D, Long, Millie D, Motwani, Kiran K, Weaver, Kimberly N, Zhang, Xian   +7 more
core   +2 more sources

Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age

New England Journal of Medicine, 2022
BACKGROUND: The safety, reactogenicity, immunogenicity, and efficacy of the mRNA-1273 coronavirus disease 2019 (Covid-19) vaccine in young children are unknown. METHODS: Part 1 of this ongoing phase 2-3 trial was open label for dose selection; part 2 was
E. Anderson, C. Creech, V. Berthaud, Arin Piramzadian, K. Johnson, M. Zervos, Fredric C. Garner, C. Griffin, Khozema Palanpurwala, M. Turner, Jeffrey Gerber, Richard L Bennett, K. Ali, Madhavi Ampajwala, Gary Berman, J. Nayak, Carey Chronis, Barbara Rizzardi, W. Muller, Christopher A Smith, G. Fuchs, Daniel S Hsia, J. Tomassini, D. DeLucia, C. Reuter, B. Kuter, Xiaoping Zhao, W. Deng, Honghong Zhou, Daniela Ramirez Schrempp, K. Hautzinger, B. Girard, K. Slobod, R. McPhee, R. Pajon, Anne Aunins, R. Das, Jacqueline M. Miller, S. Schnyder Ghamloush   +38 more
semanticscholar   +1 more source

Safety outcomes associated with the moderna COVID-19 vaccine (mRNA-1273): a literature review

Expert Review of Vaccines, 2023
Introduction Current safety data from Phase 3 clinical trials have concluded that apart from transient local and systemic reactions, no safety concerns were identified for the Moderna COVID-19 vaccine (mRNA-1273).
Angel Shabu, Prasad S. Nishtala
doaj   +1 more source

Durability of Protection Against Symptomatic COVID-19 Among Participants of the mRNA-1273 SARS-CoV-2 Vaccine Trial [PDF]

, 2022
This cohort study assesses the durability of protection against symptomatic COVID-19 among participants of the mRNA-1273 SARS-CoV-2 (Moderna) vaccine ...
Baden, Lindsey R., Corey, Lawrence, COVE Study Group, El Sahly, Hana M., Essink, Brandon, Lin, Dan-Yu, Miller, Jacqueline, Neuzil, Kathleen M.   +7 more
core   +2 more sources

Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines

Microbiology Spectrum, 2021
Studies examining antibody responses by vaccine brand are lacking and may be informative for optimizing vaccine selection, dosage, and regimens. The purpose of this study is to assess IgG antibody responses following immunization with BNT162b2 (30 μg ...
José G. Montoya, Amy E. Adams, Valérie Bonetti, Sien Deng, Nan A. Link, Suzanne Pertsch, Kjerstie Olson, Martina Li, Ellis C. Dillon, Dominick L. Frosch   +9 more
doaj   +1 more source

Hypersensitivity to the Moderna COVID-19 vaccine caused by tromethamine: PEG is not always the culprit excipient [PDF]

, 2022
Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are considered the cornerstone of the solution to the current global pandemic.
Cernada, J, Coutinho, RM, Moreira, A, Mota, D, Rama, TA   +4 more
core   +1 more source

Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial

Annals of Internal Medicine, 2022
Antinucleocapsid antibodies (anti-N Abs) are currently being used to diagnose prior SARS-CoV-2 infection in individuals and to determine community seroprevalence of SARS-CoV-2.
D. Follmann, H. Janes, O. Buhule, Honghong Zhou, B. Girard, K. Marks, K. Kotloff, Michaël Desjardins, L. Corey, K. Neuzil, Jacqueline M. Miller, Hana M. El Sahly, L. Baden   +12 more
semanticscholar   +1 more source

Risk of myocarditis following sequential doses of COVID-19 vaccine and SARS-CoV-2 infection by age and sex [PDF]

, 2022
Myocarditis is more common after severe acute respiratory syndrome coronavirus 2 infection than after COVID-19 vaccination, but the risks in younger people and after sequential vaccine doses are less certain.
Channon, Keith M, Coupland, Carol AC, Dixon, Sharon, Handunnetthi, Lahiru, Harnden, Anthony, Hippisley-Cox, Julia, Khunti, Kamlesh, Mei, Xue W, Mills, Nicholas L, Patone, Martina, Shankar-Hari, Manu, Sheikh, Aziz, Watkinson, Peter, Zaccardi, Francesco   +13 more
core   +1 more source